Literature DB >> 29629436

A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.

Haidong Dong1,2, Yiyi Yan3,4, Roxana S Dronca3, Svetomir N Markovic1,4.   

Abstract

Following antigen stimulation, the net outcomes of a T cell response are shaped by integrated signals from both positive co-stimulatory and negative regulatory molecules. Recently, the blockade of negative regulatory molecules (i.e. immune checkpoint signals) demonstrates promising therapeutic effects in treatment of human cancers, but only in a fraction of cancer patients. Since this therapy is aimed to enhance T cell responses to cancers, here we devised a conceptual model by integrating both positive and negative signals in addition to antigen stimulation that can evaluate strategies to enhance T cell responses. A digital range of adjustment of each signal is formulated in our model for prediction of a final T cell response. Our model provides a rational combination strategy for maximizing the therapeutic effects of cancer immunotherapy.

Entities:  

Year:  2017        PMID: 29629436      PMCID: PMC5884168          DOI: 10.15226/2372-0948/5/1/00155

Source DB:  PubMed          Journal:  SOJ Immunol


  25 in total

Review 1.  Natural endogenous adjuvants.

Authors:  Kenneth L Rock; Arron Hearn; Chun-Jen Chen; Yan Shi
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

Review 2.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 3.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

Review 4.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 6.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 7.  B7-H1 pathway and its role in the evasion of tumor immunity.

Authors:  Haidong Dong; Lieping Chen
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

8.  Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.

Authors:  W Scott Webster; R Houston Thompson; Kimberley J Harris; Xavier Frigola; Susan Kuntz; Brant A Inman; Haidong Dong
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 9.  Why has active immunotherapy not worked in lung cancer?

Authors:  A Thomas; G Giaccone
Journal:  Ann Oncol       Date:  2015-07-30       Impact factor: 32.976

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.